Overview

Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Bundang Hospital